Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
| العنوان: | Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer |
|---|---|
| المؤلفون: | Alexander Haug, Chrysoula Vraka, Gero Kramer, Sazan Rasul, Harald Eidherr, Werner Langsteger, Marcus Hacker, Bernhard Grubmüller, Lucia Zisser, Markus Mitterhauser, Elisabeth Kretschmer-Chott, Shahrokh F. Shariat, Tim Wollenweber |
| المصدر: | Cancers Volume 13 Issue 10 Cancers, Vol 13, Iss 2489, p 2489 (2021) |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, Anemia, Urology, urologic and male genital diseases, 030218 nuclear medicine & medical imaging, PSA, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Medicine, In patient, Lymph node, RC254-282, business.industry, Proportional hazards model, Hazard ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, mCRPC, prostate cancer, medicine.disease, PSMA-RLT, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Toxicity, Hemoglobin, business, 177Lu-PSMA |
| الوصف: | Background: We investigated the response rate and degree of toxicity of a second course of three cycles of [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) every 4 weeks in mCRPC patients. Methods: Forty-three men (71.5 ± 6.6 years, median PSA 40.8 (0.87–1358 µg/L)) were studied. The response was based on the PSA level 4 weeks after the third cycle. The laboratory parameters before and one month after the last cycle were compared. Kaplan–Meier methods were used to estimate the progression-free survival (PFS) and overall survival (OS), and the Cox regression model was performed to find predictors of survival. Results: Twenty-six patients (60.5%) exhibited a PSA reduction (median PSA declined from 40.8 to 20.2, range 0.6–1926 µg/L, p = 0.002) 18 (42%) and 8 (19%) patients showed a PSA decline of ≥50% and ≥80%, respectively. The median OS and PFS were 136 and 31 weeks, respectively. The patients with only lymph node metastases survived longer (p = 0.02), whereas the patients with bone metastases had a shorter survival (p = 0.03). In the multivariate analysis, only the levels of PSA prior to the therapy remained significant for OS (p < 0.05, hazard ratio 2.43, 95% CI 1.01–5.87). The levels of hemoglobin (11.5 ± 1.7 g/dL vs. 11 ± 1.6 g/dL, p = 0.006) and platelets (208 ± 63 g/L vs. 185 ± 63 g/L, p = 0.002) significantly decreased one month after cycle three, though only two grade 3 anemia and one grade 3 thrombocytopenia were recorded. Conclusion: A further intensive PSMA-RLT course is well tolerated in mCRPC patients and associated with promising response rates and OS. |
| وصف الملف: | application/pdf |
| تدمد: | 2072-6694 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d071d1c247d2552d7aed55cd4851a699 https://doi.org/10.3390/cancers13102489 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....d071d1c247d2552d7aed55cd4851a699 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|